Jakub P Piwowarski1,2, Anna K Kiss1, Sebastian Granica1, Thomas Moeslinger2. 1. Department of Pharmacognosy and Molecular Basis of Phytotherapy, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland. 2. Institute of Physiology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Abstract
SCOPE: Ellagitannin-rich food products and medicinal plant materials were shown to have beneficial effects toward intestinal inflammation. Due to the questionable bioavailability of ellagitannins their gut microbiota metabolites-urolithins have come to be regarded as potential factors responsible for biological activities observed in vivo. The aim of the study was to determine the influence of the three most abundant bioavailable ellagitannin gut microbiota metabolites-urolithins A, B, and C on inflammatory responses in RAW 264.7 murine macrophages, which are involved in the pathogenesis of intestine inflammation. METHODS AND RESULTS: Urolithins A, B, and C decreased NO production via inhibition of the iNOS protein and mRNA expression. They decreased the expression of IL-1β, TNF-α, and IL-6 mRNA in LPS challenged RAW 264.7 murine macrophages. A clear inhibition of NF-κB p65 nuclear translocation and p50 DNA-binding activity was associated with the observed anti-inflammatory activities of urolithins. Among the tested compounds urolithin A had the strongest anti-inflammatory activity. CONCLUSION: The anti-inflammatory effects of urolithins at concentrations that are physiologically relevant for gut tissues (≥40 μM), as revealed in this study, support the data from in vivo studies showing the beneficial effects of ellagitannin-rich products toward intestinal inflammation.
SCOPE: Ellagitannin-rich food products and medicinal plant materials were shown to have beneficial effects toward intestinal inflammation. Due to the questionable bioavailability of ellagitannins their gut microbiota metabolites-urolithins have come to be regarded as potential factors responsible for biological activities observed in vivo. The aim of the study was to determine the influence of the three most abundant bioavailable ellagitannin gut microbiota metabolites-urolithins A, B, and C on inflammatory responses in RAW 264.7 murine macrophages, which are involved in the pathogenesis of intestine inflammation. METHODS AND RESULTS:Urolithins A, B, and C decreased NO production via inhibition of the iNOS protein and mRNA expression. They decreased the expression of IL-1β, TNF-α, and IL-6 mRNA in LPS challenged RAW 264.7 murine macrophages. A clear inhibition of NF-κB p65 nuclear translocation and p50 DNA-binding activity was associated with the observed anti-inflammatory activities of urolithins. Among the tested compounds urolithin A had the strongest anti-inflammatory activity. CONCLUSION: The anti-inflammatory effects of urolithins at concentrations that are physiologically relevant for gut tissues (≥40 μM), as revealed in this study, support the data from in vivo studies showing the beneficial effects of ellagitannin-rich products toward intestinal inflammation.
Authors: Dongryeol Ryu; Laurent Mouchiroud; Pénélope A Andreux; Elena Katsyuba; Norman Moullan; Amandine A Nicolet-Dit-Félix; Evan G Williams; Pooja Jha; Giuseppe Lo Sasso; Damien Huzard; Patrick Aebischer; Carmen Sandi; Chris Rinsch; Johan Auwerx Journal: Nat Med Date: 2016-07-11 Impact factor: 53.440
Authors: Chun W Mai; Kok S I Yap; Mee T Kho; Nor H Ismail; Khatijah Yusoff; Khozirah Shaari; Swee Y Chin; Erin S H Lim Journal: Front Pharmacol Date: 2016-02-02 Impact factor: 5.810
Authors: Aneta Bobowska; Sebastian Granica; Agnieszka Filipek; Matthias F Melzig; Thomas Moeslinger; Jürgen Zentek; Aleksandra Kruk; Jakub P Piwowarski Journal: Eur J Nutr Date: 2020-09-22 Impact factor: 5.614
Authors: Kristen M Roberts; Elizabeth M Grainger; Jennifer M Thomas-Ahner; Alice Hinton; Junnan Gu; Ken Riedl; Yael Vodovotz; Ronney Abaza; Steven J Schwartz; Steven K Clinton Journal: Mol Nutr Food Res Date: 2020-03-17 Impact factor: 6.575